# **PCI BIOTECH**

Unlocking the potential of innovative medicines

Q2 & 1H 2017 PRESENTATION August 29, 2017 Per Walday, CEO Ronny Skuggedal, CFO

Viel as With a surger



## PCI BIOTECH

### Important notice and disclaimer

This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on PCI Biotech's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "programmes", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of PCI Biotech's strategy and its ability to further grow, risks associated with the development and/or approval of PCI Biotech's products candidates, ongoing clinical trials and expected trial results, the ability to commercialise fimaporfin (Amphinex<sup>®</sup>), technology changes and new products in PCI Biotech's potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The reservation is also made that inaccuracies or mistakes may occur in this information given about current status of the Company or its business. Any reliance on the information is at the risk of the reader, and PCI Biotech disclaims any and all liability in this respect.



### HIGHLIGHTS ► 2017

fima CHEM	<ul> <li>Encouraging interim overall survival data from Phase I</li> <li>First patient treated in the Phase I extension study</li> </ul>
fima VACC	<ul> <li>Tolerability of the vaccination technology established – awaiting initial results on overall T-cell responses</li> </ul>
fima NAc	<ul> <li>RXi Pharmaceutical collaboration expanded into the field of immuno-oncology</li> <li>Top-10 pharma collaboration extended and entered into <i>in vivo</i> studies</li> </ul>
Corporate	<ul> <li>Dr Hans Olivecrona appointed Chief Medical Officer</li> <li>Completion of a fully underwritten rights issue of NOK 70 million</li> <li>Awarded up to NOK 14.3 million for further development of the vaccination platform</li> </ul>



## PCI BIOTECH AT A GLANCE

Unlocking the potential of innovative medicines

- A listed (PCIB:NO) cancer-focused biotech company
- Photochemical internalisation ("PCI") technology, originating from the Norwegian Radium Hospital


Programme	Indications / Therapeutics	Preclinical	Phase I	Phase II	Status
fima <i>Chem</i>	Bile duct cancer / gemcitabine				Phase I extension initiated to evaluate safety of repeated treatment in the orphan indication bile duct cancer
<b>O</b> fima VACC	Therapeutic cancer vaccines				Phase I study in healthy volunteers One active R&D collaboration
fimaNAc	Nucleic acid therapeutics				Four active R&D collaborations

An oncology focused company with three well differentiated assets



### **PCI** TECHNOLOGY

Enabling drugs to reach intracellular therapeutic targets



PCI – the solution to a key challenge for several modalities






## THE SOLUTION TO A KEY CHALLENGE

Three well-defined development programmes

#### fima*Снем*



- First-in-man study published in Lancet Oncology\*
- Promising tumour responses in Phase I in inoperable extrahepatic bile duct cancer
- ► Incidence close to 15,000 (Eur.+US), with ≈3,000 assumed eligible for fima CHEM
- Possible upside in distal and metastatic disease, and in Asia
- Orphan disease with high price potential



\$7,5bn

in 2022\*\*

- Expected market growth largely driven by therapeutic vaccine combinations with checkpoint inhibitors
- Aim is to out-license the technology on non-/semi-exclusive basis
- Opportunity to develop own therapeutic vaccination products




- Estimated sales of \$18bn in 2030\*\*\* (RNAi alone)
- Opportunistic collaborative approach
- Aim is to out-license the technology on non-/semi-exclusive basis



- Lancet Oncology (2016) **17**(9): p1217–1229
- \*\* GBI Research (2016) Global Cancer Vaccines Market to 2022
- \*\*\* Research and Markets (2015) RNAi therapeutics market

# PCI TECHNOLOGY fimaCHEM – mode of action



### BILE DUCT CANCER

### Excellent fit between medical need and fimaCHEM


Combination therapy with gemcitabine and cisplatin Enhancing the active Orphan indication, yearly incidence rate of 1-2 per is recommended and recommended 100,000 in the western world - higher in Asia Gemcitabine is significantly enhanced by fimaCHEM chemotherapy Conjoining localised with systemic therapy ► Five-year survival rate of less than 5% and almost 0% when inoperable Patients are treated with endoscopic methods Easy illumination ► Average survival inoperable: ≈12 months (ERCP) for diagnosis and stenting through standard Optic fibre and illumination easily included in the • endoscopic methods Current management **ERCP** procedure Surgery - Only potentially curative treatment Tumours tend to block the bile duct **Boosting chemotherapy** - Less than <sup>1</sup>/<sub>3</sub> are resectable at presentation Liver function is often affected effect where it is most Biliary drainage is key for patient treatment and needed Stenting survival - Endoscopic stenting for palliative biliary drainage Chemotherapy Preclinical and clinical data supports the notion of potential abscopal effects with fimaCHEM No approved chemotherapy Inducing immunogenic May be ideal for combination with checkpoint tumour cell death - Recommended: gemcitabine and cisplatin inhibitors



### BILE DUCT CANCER – CLINICAL PHASE I/II STUDY

Encouraging early signs of efficacy in Phase I

Interim average overall survival (OS) of all 16 patients in Phase I was 15.6 months at end of July 2017, with 25% of the patients still being alive. Median OS ended at 14.4 months.




Best Overall Response (all radiologically evaluable patients) – 90% showed tumour reduction

### INOPERABLE EXTRAHEPATIC BILE DUCT CANCER

An underserved patient population

No approved medical treatment

Combination therapy with gemcitabine and cisplatin recommended






### INOPERABLE EXTRAHEPATIC BILE DUCT CANCER

An underserved patient population

No approved medical treatment


Combination therapy with gemcitabine and cisplatin recommended






### BILE DUCT CANCER – PHASE I EXTENSION STUDY

Repeating the fima CHEM treatment with the aim to further enhance efficacy



- Exploring safety of repeating the fimaCHEM treatment in an extension to Phase I
- The study is done in parallel with other preparations for the next phase
- May allow for repeated treatment in a potential pivotal Phase II study





### INOPERABLE EXTREHEPATIC BILE DUCT CANCER

Status and strategy going forward

#### Phase I completed with good tolerability and promising early signs of efficacy

- Tumour shrinkage in almost all radiologically evaluable patients
- Interim average overall survival (OS) of 15.6 months with 25% of patients still alive; median OS ended at 14.4 months

#### Exploring safety of repeated treatment as a Phase I extension

First patient included in August 2017

#### Regulatory interactions with authorities to determine fastest way to market

The interactions are continuing into 2H 2017

#### Orphan designation

- Granted in EU
- US application submitted interaction with the FDA to ensure a quickest possible process


#### Engaging US key opinion leaders (KOL's)


Involving US KOL's in the study design discussion for Phase II



fima VACC

# PCI TECHNOLOGY fime VACC – mode of action





#### fima VACC

## PROGRESSING CLINICAL TRANSLATION


Phase I study in healthy volunteers


- Overall objective:
  - Determine the safety, tolerability and immune response of fima VACC in healthy subjects
- Study consists of three parts:
  - 1. Tolerability of intradermal fimaporfin, adjuvant and light (without vaccine)
  - 2. fima VACC vaccination: dose finding (fimaporfin and light) and cohort expansion
  - 3. Optimisation of the fima VACC regimen
- Status:
  - More than 50 subjects have so far been included and treated
  - Part 1 is completed
  - Part 2 is ongoing
    - Maximum tolerated dose not yet identified  $\rightarrow$  total number of subjects may increase with up to 30
    - Delay in establishing immune response assay  $\rightarrow$  initial results will now include a larger proportion of subjects
- Timelines:
  - Q3 2016: First subject dosed
  - 2H 2017: Read-out of initial results on overall T-cell responses from >50% of subjects in part 2



#### fima*NAc*

# PCI TECHNOLOGY fimaNAc - mode of action





### RESEARCH COLLABORATIONS

Ultimovacs

► Five active collaborations within nucleic acid therapeutics and vaccination

fima <i>NAC</i>	RXi Pharmaceuticals				
R X i	<ul> <li>Initiated Q2 2015. Listed on Nasdaq, developing innovative therapeutic siRNA</li> <li>Q2'17: Collaboration expanded to immuno-oncology following RXi's MirImmune acquisition</li> </ul>				
	Top-10 large pharma				
	<ul> <li>Initiated Q3 2015. A global leader in nucleic acid therapeutics</li> <li>Q2'17: Collaboration extended to end of 2017 and expanded to in vivo studies</li> </ul>				
	BioNTech				
BIONTECH	<ul> <li>Initiated Q3 2016. German biotech company developing individualised cancer immunotherapies</li> <li>Clinical programmes in melanoma, head &amp; neck, breast, ovarian and pancreatic cancer</li> </ul>				
0_	eTheRNA				
eTheRNA	<ul> <li>Initiated Q4 2016. A global leader in mRNA-based immunotherapies</li> <li>Evaluate synergistic effects between companies' technologies</li> </ul>				
fima <i>VACC</i>	Ultimovacs				
	<ul> <li>Initiated 01 2016 Norwegian immunotherapy company</li> </ul>				

- Initiated Q1 2016. Norwegian immunotherapy company
   Therapoutic capeer vaccine against human telemorase
- Therapeutic cancer vaccine against human telomerase



## FINANCE

### ► Key financial figures and top 10 shareholders

(In NOK 1,000)	2017	2017	2016	2016	201
	1H	Q2	1H	Q2	F
Other income	4 833	2 405	4 917	2 332	10 47
Operating costs	21 892	9 611	21 506	11 613	43 50
Operating results	-17 059	-7 205	-16 589	-9 281	-33 02
Financial items	403	181	283	111	84
Comprehensive income	-16 657	-7 024	-16 306	-9 170	-32 18
Cash & cash equivalents	60 700	60 700	31 028	31 028	14 00
Net cash flow from operating activities	-18 334	-9 229	-18 221	-8 607	-35 24

- Close to NOK 10 million in non-dilutive funding for 2017
- Cash burn 1H 2017 in line with last year
- Cash position to reach strategic milestones

RADIUMHOSPITALETS FORSKNINGSSTIFTELSE       1 597 274       6         MP PENSJON PK       1 447 504       5         NORDNET LIVSFORSIKRING       737 618       2         GRESSLIEN ODD ROAR       556 000       2         MYRLID AS       555 900       2         BERG-LARSEN ALEXANDER       509 435       2         NORDNET BANK AB       445 312       1         SYVERTSEN SVEIN ERIK       437 107       1         AASEN KJETIL MYRLID       400 000       1         Total 10 largest shareholders       9 226 990       37		Number	%
MP PENSJON PK       1 447 504       5         NORDNET LIVSFORSIKRING       737 618       2         GRESSLIEN ODD ROAR       556 000       2         MYRLID AS       555 900       2         BERG-LARSEN ALEXANDER       509 435       2         NORDNET BANK AB       445 312       1         SYVERTSEN SVEIN ERIK       437 107       1         AASEN KJETIL MYRLID       400 000       1         Total 10 largest shareholders       9 226 990       37	VANSE AS	2 540 840	) 10,20
NORDNET LIVSFORSIKRING737 618GRESSLIEN ODD ROAR556 000MYRLID AS555 900BERG-LARSEN ALEXANDER509 435NORDNET BANK AB445 312SYVERTSEN SVEIN ERIK437 107AASEN KJETIL MYRLID400 000Total 10 largest shareholders9 226 990	HOSPITALETS FORSKNINGS	STIFTELSE 1 597 274	6,41
GRESSLIEN ODD ROAR       556 000       2         MYRLID AS       555 900       2         BERG-LARSEN ALEXANDER       509 435       2         NORDNET BANK AB       445 312       1         SYVERTSEN SVEIN ERIK       437 107       1         AASEN KJETIL MYRLID       400 000       1         Total 10 largest shareholders       9 226 990       37	ISJON PK	1 447 504	5,81
MYRLID AS555 9002BERG-LARSEN ALEXANDER509 4352NORDNET BANK AB445 3121SYVERTSEN SVEIN ERIK437 1071AASEN KJETIL MYRLID400 0001Total 10 largest shareholders9 226 99037	ET LIVSFORSIKRING	737 618	3 2,96
BERG-LARSEN ALEXANDER         509 435         2           NORDNET BANK AB         445 312         1           SYVERTSEN SVEIN ERIK         437 107         1           AASEN KJETIL MYRLID         400 000         1           Total 10 largest shareholders         9 226 990         37	LIEN ODD ROAR	556 000	) 2,23
NORDNET BANK AB445 312SYVERTSEN SVEIN ERIK437 107AASEN KJETIL MYRLID400 000Total 10 largest shareholders9 226 990	AS	555 900	) 2,23
SYVERTSEN SVEIN ERIK437 1071AASEN KJETIL MYRLID400 0001Total 10 largest shareholders9 226 99037	ARSEN ALEXANDER	509 43	5 2,05
AASEN KJETIL MYRLID400 0001Total 10 largest shareholders9 226 99037	ET BANK AB	445 312	2 1,79
Total 10 largest shareholders9 226 99037	ÍSEN SVEIN ERIK	437 107	1,76
0	KJETIL MYRLID	400 000	) 1,61
	largest shareholders	9 226 990	37,05
Total other shareholders 15 673 400 62	er shareholders	15 673 400	62,95
Total number of shares 24 900 390 100	nber of shares	24 900 390	100,00



### GOOD PROGRESS IN ALL AREAS ► 2017

- ✓ **fima***CHEM* Initiated patient enrolment in the extension of Phase I
- ✓ **fima** VACC Tolerability of the vaccination technology established
- ✓ **fimaNAc** Preclinical research collaborations entering new stages
- ✓ **Finance** Secured financing to reach strategic milestones
- ✓ **Corporate** Strengthened the organisation with Dr Olivecrona as CMO



# KEY MILESTONES ANTICIPATED ► Through 1H 2018

#### 2H 2017 > fimaCHEM Regulatory clarity on fastest way to market

- 2H 2017 > fima VACC Initial results on overall T-cell responses in Phase I
- 1H 2018 > fimaCHEM Safety read-out of Phase I extension
- 1H 2018 > fimaCHEM Initiation of Phase II
- 1H 2018 > fima VACC Phase I in healthy volunteers completed



### **PCI BIOTECH**

### Summary and outlook

fimaCHEM – Progressing development in bile duct cancer

- Encouraging tumour response and survival data
- Initiated enrolment into Phase I extension
- Ongoing regulatory interactions to determine fastest way to market
- Engaging US KOL's to build awareness and discuss clinical design, preparing for Phase II
- **fima** *VACC* Clinical validation of the vaccination technology
  - Tolerability established awaiting initial results on overall T-cell reponses
- fimaNAc Progressing the research collaborations
  - Focusing the RXi collaboration on immuno-oncology
  - Top-10 pharma collaboration extended and entered into in vivo studies
- Cash position to reach strategic milestones



## PCI BIOTECH HOLDING ASA

Enquiries

CEO Per Walday Cell phone: +47 917 93 429 Telephone: +47 67 11 54 00 E-mail: <u>pw@pcibiotech.com</u>

CFO Ronny Skuggedal Cell phone: +47 940 05 757 Telephone: +47 67 11 54 00 E-mail: <u>rs@pcibiotech.com</u>

www.pcibiotech.com

